



FIG S1

a HexaBody-CD38 (IgG1-3003-028-E430G)



b daratumumab



c isatuximab




FIG S2




FIG S3




FIG S4






FIG S5

a CD46



b CD55



c CD59




FIG S6






FIG S7


a ADCC



b ADCP - loss of Daudi cells



c ADCP - phagocytic activity



d Trogocytosis




FIG S8






FIG S9

a



b



c




FIG S10

